Abstract
Multiple myeloma (MM) is a plasma cell neoplasm accounting for 1% of all malignancies. It is characterized by a monoclonal malignant proliferation of plasma cells accompanied by an increase in M-protein. Plasmablastic myeloma represents 5-15% of the cases of multiple myeloma. This morphology of a MM is an independent predictor of poor survival. Plasmablastic myeloma tends to have worse outcomes than other plasma cell dyscrasias. The median survival of these patients is around 1.9 years. Much of our knowledge on plasmablastic variant of MM is dependent on case reports and case series. Hence, an early identification of this aggressive variant of multiple myeloma and its differentiation from hematological malignancy like plasmablastic lymphoma is necessary for optimal patient management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.